Oxford Biomedica PLC Block listing application

RNS Number : 1090B

Oxford Biomedica PLC

26 January 2024

 

 

 

 

Oxford Biomedica plc

Additional Listing in connection with acquisition of ABL Europe

 

Oxford, UK - 26 January 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that  application has been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for the listing of 3,149,374 new ordinary shares of 50 pence each (the "Consideration Shares") in relation to the acquisition of ABL Europe SAS as announced on 20 September 2023 and 4 December 2023.

 

The acquisition of ABL Europe SAS is expected to complete on 29 January 2024 and it is expected that admission to the Official List and the London Stock Exchange of the Consideration Shares will become effective on the same day. The Consideration Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

 

-Ends-

 

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

ALSBUGDBRGDDGSL